References
- Brown HS, Ito K, Galetin A, Houston JB. (2005). Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60:508–18.
- Brown HS, Griffin M, Houston JB. (2007). Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos 35:293–301.
- Di L. (2017). Reaction phenotyping to assess victim drug-drug interaction risks. Expert Opin Drug Discov 12:1105–15.
- Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. (2009). Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: impact of plasma and microsomal binding. Xenobiotica 39:227–35.
- Hallifax D, Foster JA, Houston JB. (2010). Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150–61.
- Komatsu T, Yamazaki H, Asahi S, et al. (2000). Formation of a dihydroxy metabolite of phenytoin by human liver microsomes/cytosol: roles of cytochrome P450 2C9, 2C19, and 3A4. Drug Metab Dispos 28:1361–8.
- Ludden LK, Ludden TM, Collins JM, et al. (1997). Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. J Pharmacol Exp Ther 282:391–6.
- Murayama N, Yajima K, Hikawa M, et al. (2018). Assessment of multiple cytochrome P450 activities in metabolically inactivated human liver microsomes and roles of P450 2C isoforms in reaction phenotyping studies. Biopharm Drug Dispos 39:116–21.
- Nakanishi K, Uehara S, Kusama T, et al. (2018). In vivo and in vitro diclofenac 5-hydroxylation mediated primarily by cytochrome P450 3A enzymes in common marmoset livers genotyped for P450 2C19 variants. Biochem Pharmacol 152:272–8.
- Ohyama K, Murayama N, Shimizu M, Yamazaki H. (2014). Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. Xenobiotica 44:10–6.
- Peng Y, Wu H, Zhang X, et al. (2015). A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation. Xenobiotica 45:961–77.
- Poulin P, Kenny JR, Hop CE, Haddad S. (2012). In vitro-in vivo extrapolation of clearance: modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. J Pharm Sci 101:838–51.
- Rowland A, Gaganis P, Elliot DJ, et al. (2007). Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137–47.
- Sekiguchi K, Kanazu T, Murayama N, et al. (2016). In vitro inhibition and enhancement of liver microsomal S-777469 metabolism by long-chain fatty acids and serum albumin: insight into in vitro and in vivo discrepancy of metabolite formation in humans. Xenobiotica 46:495–502.
- Tracy TS, Rosenbluth BW, Wrighton SA, et al. (1995). Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 49:1269–75.
- Uehara S, Uno Y, Inoue S, et al. (2015). Novel marmoset cytochrome P450 2C19 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-warfarin, tolbutamide, flurbiprofen, and omeprazole. Drug Metab Dispos 43:1408–16.
- Uehara S, Uno Y, Tomioka E, et al. (2017). Functional characterization and tissue expression of marmoset cytochrome P450 2E1. Biopharm Drug Dispos 38:394–7.
- Uehara S, Inoue T, Utoh M, et al. (2016). Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica 46:163–8.
- Wattanachai N, Polasek TM, Heath TM, et al. (2011). In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol 67:815–24.
- Wattanachai N, Tassaneeyakul W, Rowland A, et al. (2012). Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance. Drug Metab Dispos 40:982–9.
- Yamazaki H, Inoue K, Shimada T. (1998). Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 28:103–15.
- Yamazaki H, Kunikane E, Nishiyama S, et al. (2015). Human plasma concentrations of tolbutamide and acetaminophen extrapolated from in vivo animal pharmacokinetics using in vitro human hepatic clearances and simple physiologically based pharmacokinetic modeling for radio-labeled microdose clinical studies. Radioisotopes 64:509–19.
- Zhou Q, Matsumoto S, Ding LR, et al. (2004). The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. Life Sci 75:2145–55.